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Objectives. To evaluate prostate cancer (PCa) detection rates of real-time elastography (RTE) in dependence of tumor size, tumor
volume, localization and histological type. Materials and Methods. Thirdy-nine patients with biopsy proven PCa underwent RTE
before radical prostatectomy (RPE) to assess prostate tissue elasticity, and hard lesions were considered suspicious for PCa. After
RPE, the prostates were prepared as whole-mount step sections and were compared with imaging findings for analyzing PCa
detection rates. Results. RTE detected 6/62 cancer lesions with a maximum diameter of 0–5mm (9.7%), 10/37 with a maximum
diameter of 6–10mm (27%), 24/34 with a maximum diameter of 11–20 20 mm (70.6%), 14/14 with a maximum diameter of
>20mm (100%) and 40/48 with a volume ≥0.2 cm3 (83.3%). Regarding cancer lesions with a volume ≥ 0.2 cm3 there was a
significant diﬀerence in PCa detection rates between Gleason scores with predominant Gleason pattern 3 compared to those with
predominant Gleason pattern 4 or 5 (75% versus 100%; P = 0.028). Conclusions. RTE is able to detect PCa of significant tumor
volume and of predominant Gleason pattern 4 or 5 with high confidence, but is of limited value in the detection of small cancer
lesions.
1. Introduction
Diagnosis and therapy of prostate cancer (PCa) are discussed
controversially. On the one hand, prostate-specific antigen
(PSA) testing has low specificity for PCa detection and sys-
tematic biopsy low sensitivity, and on the other hand detec-
tion of insignificant PCa may lead to overdiagnosis and over-
therapy with its cost and complications [1–3]. Strategies like
active surveillance, watchful waiting, and focal therapy of
index cancer lesions are becoming more popular [3, 4].
Imaging modalities like magnetic resonance imaging
(MRI), novel transrectal ultrasound (TRUS) technologies,
that is, contrast enhanced TRUS (CE-TRUS), or real-time
elastography (RTE) and computer aided analysis of TRUS
signals (i.e., HistoScanning or computerized TRUS with
artificial neural network analysis) have shown to be helpfully
in urological management of diagnosis and/or therapy
strategies for PCa [5–8]. One of the key requirements of
imaging is to demonstrate significant cancer lesions in the
prostate with high confidence, since they may determine the
clinical prognosis [4, 9]. Targeted biopsy, focal therapy, and
therapy monitoring of these lesions then could become
possible. Based on the tumor volume significant lesions are
defined to be ≥0.2 cm3 or ≥0.5 cm3 [10, 11].
One possibility for visualization of PCa is the representa-
tion of tissue elasticity. Usually cancers have a higher cell and
vessel density than normal tissue and are therefore associated
with a decreased elasticity [12, 13]. This is similar to the dig-
ital rectal examination (DRE) of the prostate performed by
the urologists, where hard palpable areas are classified as
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Figure 1: Hard area PZ mid-gland left measured with 7.6mm in the axial plane ((a), white arrow) and with 19.4mm in the sagittal plane
((b), white arrows).
suspicious for PCa. However, only the posterior parts of the
prostate can be evaluated by DRE [14]. RTE, an ultrasonic
method which is able to demonstrate tissue elasticity color-
coded, does not have this problem, since all anatomical
regions of the peripheral zone (PZ) can be evaluated [6].
Furthermore, this noninvasive technique is time-and cost-
eﬀective and proved its potentials in PCa detection with
promising results in former studies [14, 15]. In contrast to
static MRI, targeted biopsy and focal therapy of the prostate
can be done under real-time conditions with RTE.
The aim of this study was to evaluate PCa detection rates
of RTE in dependence of tumor size, tumor volume, localiza-
tion, and histological type and to determine reasons for false
negative findings.
2. Materials andMethods
2.1. Patients. From April 2010 to November 2011 39 con-
secutive patients with a median age of 63 years (range: 48–
75 years) and a median serum PSA value of 5 ng/mL (range:
2.1–14 ng/mL) participated in this prospective single-center
study. All patients were informed about the study design and
the study objective. Written informed consent and a positive
vote by the local ethics committee of Innsbruck were present.
Men with biopsy proven PCa and who were scheduled for
radical prostatectomy (RPE) were included. All participants
underwent RTE before RPE, and after RPE the prostates were
prepared as whole-mount step sections, and the boarder of
cancer lesions were marked. DRE was not part of the study.
2.2. Real-Time Elastography. RTE was done by one expe-
rienced uroradiologist (F. Aigner) on a EUB 8500 Hitachi
ultrasound unit (Hitachi medical systems, Tokyo, Japan)
using a 7.5MHz end fire transrectal probe to assess tissue
elasticity. Elastograms were obtained by slight prostate com-
pression and decompression, which was manually induced
by the investigator using the transrectal probe and con-
trolled by the compression indicator on the monitor. Hard
areas were considered PCa suspicious and color coded
blue (Figure 1). These areas were reproducible in the axial
and sagittal planes using a previously described approach
[16]. Imaging findings suspicious for PCa were assigned to
anterior, posterior, right, and left parts of the peripheral
zone (PZ) of the prostate only, since most cancers originate
from this zone and furthermore, transitional zone cancers are
more likely to be less aggressive [17, 18].
2.3. Histopathology: Preparation, Reporting, and Correlation
with RTE Findings. After RPE and fixation, the prostatec-
tomy specimens were laminated in 4mm thick slices with an
orientation of 90◦ to the urethra and prepared according to
the Stanford protocol. Pathological analysis was performed
by one dedicated uropathologist (G. Scha¨fer), who outlined
every cancer lesion and reported an assigned Gleason score.
Tumor measures were provided in consideration of a shrink-
age factor. The whole-mount step sections have been scanned
in our system and were used in digital form for a correlation
with the data of imaging findings. The PZ was divided in
anterior, posterior, right, and left parts and the limit between
anterior and posterior part was defined as the section run-
ning through the widest transverse diameter of the prostate.
Based on histopathology, the lesions were classified
according to their maximal diameter in the following 4
categories: lesions with a maximum diameter of 0–5mm, 6–
10mm, 11–20mm, and >20mm. Furthermore, lesions were
classified to their tumor volume in the following 2 categories:
lesions with a volume of ≥0.2 cm3 and ≥0.5 cm3.
2.4. Statistical Analysis. Cancer detection rates based on
tumor size and tumor volume as well as patient character-
istics were summarized with frequencies and percentages or
with median, range, minimum, and maximum values. The
chi-square test was used to calculate significant diﬀerences
between PCa detection rates based on localization, prostate
volume (PV), tumor size, Gleason Scores, and serum PSA
values. All statistical calculations were performed using SPSS
18.0 software, and a P < 0.05 was considered statistically
significant.
3. Results
Overall, histological examination of the 39 prostatectomy
specimens showed 147 cancer lesions in the PZ with a
median size of 7.7mm (range: 2–30.8mm) of which 43
(29.3%) were localized in the anterior part, 90 (61.2%) in
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Figure 2: Detection rate based on tumor size.
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Figure 3: Detection rate based on tumor volume.
the posterior part, and 14 (9.5%) in both anterior and
posterior parts of the prostate. RTE detected a total of 54
cancer lesions out of the 147 (36.7%). The median volume
when only including tumors ≥0.2 cm3 was 0.85 cm3 (range:
0.21–11.18 cm3). The median Gleason score of all cancer
lesions was 6 (range: 5–10) and of cancer lesions ≥0.2 cm3
was 7 (range: 6–10).
3.1. PCa Detection Rates in Dependence of Tumor Size
(Figure 2). RTE detected 6 of 62 cancer lesions with a
maximum diameter of 0–5mm (9.7%), 10 of 37 with a
maximum diameter of 6–10mm (27%), 24 of 34 with a
maximum diameter of 11–20mm (70.6%) and, 14 of 14 with
a maximum diameter of >20mm (100%).
3.2. PCa Detection Rates in Dependence of Tumor Vol-
ume (Figure 3). RTE detected 40 of 48 cancer lesions with a
tumor volume ≥0.2 cm3 (83.3%) and 31 of 34 with a tumor
volume ≥0.5 cm3 (91.2%).
Table 1: Detection rate of all lesions ≥0.2 cm3 in dependence
of localization, Gleason scores, prostate volumes and PSA serum
values; n = 48.
Detection P
Localization
Anterior 66.7% (6/9)
0.419Posterior 80% (20/25)
Both 100% (14/14)
Gleason score
G5, G6, G7 (3+4) 75% (24/32)
0.028
G7(4+3), G8, G9, G10 100% (16/16)
PV (mL)
<40 86.8% (33/38)
0.204≥40 70% (7/10)
PSA (ng/mL)
<4 84.6% (11/13)
0.885≥4 82.9% (29/35)
3.3. PCa Detection Rates Including all Cancer Lesions≥0.2 cm3
in Dependence of Localization, Gleason Scores, Prostate Vol-
umes, and PSA Values (Table 1). RTE detected 6 of 9 cancer
lesions in the anterior part (66.7%; group 1), 20 of 25 cancer
lesions in the posterior part (80%; group 2), and 14 of 14, if
the cancer lesions were located in both anterior and posterior
parts (100%; group 3). PCa detection was not significantly
diﬀerent between group 1 and 2 (P = 0.419).
There was no significant diﬀerence for PCa detection in
prostate volumes <40mL and ≥40mL (P = 0.204) and at
serum PSA values <4 ng/mL and ≥4 ng/mL (P = 0.885).
A significant diﬀerence in PCa detection was found for
PCa with a predominant Gleason pattern ≤3 and ≥4 (P =
0.028).
3.4. False Negative Findings on RTE for Cancer Lesions
≥0.2 cm3. All 8 missed cancer lesions ≥0.2 cm3 had a pre-
dominant Gleason pattern of 3. Six of these eight lesions had
sparse architecture on histology, which is despite the malig-
nant components composed of normal glands and glands
with dilated lumina. Only two lesions were dense and had
tumor volumes of 0.41 cm3 and 0.22 cm3, respectively.
4. Discussion
A total of 26% (10/39) of our study population had serum
PSA values <4 ng/mL at time of biopsy and have been cancer
positive. This suggests that there is no suﬃcient PSA cutoﬀ
which allows excluding PCa. Thompson et al. and our study
group demonstrated this fact in former studies [19, 20].
Therefore, imaging modalities to visualize PCa should
raise the confidence for PCa detection independently of
serum PSA values and should demonstrate significant cancer
disease with high sensitivities. Detecting insignificant disease
may lead to overdiagnosis and overtherapy [3]. Some authors
define cancer lesions <0.5 cm3 as insignificant, whereas other
prefer a treshold of <0.2 cm3 [10, 11]. In our series, RTE
was capable to demonstrate 83.3% of all cancer lesions with
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Figure 4: Outlined large cancer lesion PZ midgland right on whole-mount step section shown on (a) and corresponding hard area (white
arrows) on elastogram (b) in axial planes.
(a) (b)
Figure 5: Outlined small cancer lesion PZ base right on whole-mount step section shown on (a) and corresponding elastogram on (b) in
axial plane with arrow marked soft base.
a tumor volume ≥0.2 cm3 and 91.2% with a tumor volume
of ≥0.5 cm3 (Figure 4).
Regarding the largest diameter the detection rate in the
group 0–5mm was weak with 9.7%, also not satisfying in
the group 6–10mm with 27% (Figure 5). However, as stated
above: should we really be able to detect those small cancer
lesions?
Roethke et al. investigated tumor size dependent detec-
tion rates of well-established T2 weighted magnetic reso-
nance imaging (T2w-MRI) and found sensitivities of 45%
and 89% for lesions with a maximum size of 10–20mm and
>20mm, which is slightly lower than our results (70.6% and
100%; resp.) [21]. Furthermore, they concluded that T2w-
MRI cannot exclude PCa with lesions smaller 10mm and
0.4 cm3 and that including foci smaller 10mm or less than
0.5 cm3 decreased sensitivity clearly. Similar to our results,
the presented data suggest that generally imaging of PCa is
limited due to tumor size. Nevertheless, they considered their
detection rate for lesions more than 20mm (1.6 cm3) as high
[21].
In contrast, Walz et al. concluded that RTE alone did not
allow the identification of the PCa index lesion with satis-
factory reliability, which should be necessary for focal ther-
apy. They compared RTE findings with whole-mount step
sections to evaluate the diagnostic accuracy for identifying
the PCa index lesion, which is considered to be responsible
for possible metastatic progression and cancer-specific death
and observed a sensitivity of only 58.8% [4].
Sumura et al. reported sensitivities for RTE of 72.7% for
tumors with volume <0.1 cm3, 77.8% for tumors with vol-
ume 0.1–0.3 cm3, 71.4% for tumors with volume >0.3 cm3,
and 100% for tumors with volume >0.5 cm3 [22]. Similar to
our study, the detection rates for both anterior and posterior
tumors were nearly equal. Furthermore, our data indicate
that PV and PSA serum values have no significant influence
for detection rates in significant disease (Table 1).
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Figure 6: Outlined sparse cancer lesion PZ base right on whole-mount step section (a), no suspicious changes on macroscopic specimen
(b), elastogram (c), and grey-scale ultrasound (d).
Nevertheless, we missed 8 of 48 cancer lesions with a
tumor volume >0.2 cm3 on RTE, which means nearly 20% of
significant disease. Our pathologist reevaluated the whole-
mount step sections of these 8 cases and all missed cancer
lesions had a predominant Gleason pattern 3 and no cancer
lesion with predominant Gleason pattern of 4 or 5 was
missed.
In total, 6 of the 8 cancer lesions showed sparse architec-
ture on histology, which means they were intermixed with
normal glands and also with glands showing dilated lumina
and so are more fluid and therefore soft which is a limitation
for RTE (Figure 6). The 2 other cases were dense tumors and
had volumes of 0.22 cm3 and 0.41 cm3. This fact was also
described by Langer et al. who investigated the outcome of
diﬀusion weightedMRI (DWI) and T2w-MRI in dependence
of histological tumor composition [23]. Similar to RTE, DWI
assesses tissue information due to cell density: the denser
the cancer, the higher the diﬀusion restriction. All of their
“invisible” tumors also had predominant Gleason pattern 3
and showed sparse architecture on histology, so that they
did not significantly diﬀer from healthy prostate tissue. The
authors concluded that this may limit T2w-MRI and DWI in
the detection and the assessment of tumor volume of some
cancers.
Some cancer lesionsmay be negative on RTE, but positive
on CE-TRUS [20].Maybe this multiparametric way—adding
tissue informations about contrast media dynamics to grey-
scale ultrasound and RTE—could have detected some of our
false negative findings. Brock et al. have shown the usefulness
of this approach, whereas Nyga˚rd et al. demonstrated the
benefit of adding new biomarkers, like PCA-3, to RTE find-
ings for the detection of significant disease [24, 25].
Our study has several limitations. (1)We do not have data
about intra- and interobserver variability. (2) We have used
only one US system for RTE. The reproducibility of our
results with other US systems needs to be evaluated in further
studies. (3) We focused this study on correlating tumor sizes;
we did not correlate right negative results between RTE and
histopathologic specimens. (4) We investigated the PZ only
due to the above mentioned reasons. (5) We knew that every
patient had PCa, which is a bias. (6) The planes of whole-
mount step sections had an orientation of 90◦ to the urethra,
while an endfire transducer provides images in diﬀerent
angles. Therefore it could be diﬃcult to be sure, whether the
identical geographic areas were compared. An investigation
with 3D/4D ultrasound would be desirable.
5. Conclusion
RTE is capable of detecting significant PCa with high sensi-
tivity, but can have problems when visualizing tumors with
sparse architecture. Therefore, adding information about
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contrast media dynamics in a multiparametric way may
decrease the number of false negative cases. In the detection
of smaller cancer lesions, RTE is of limited value.
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